Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Pharmacological characterization of lipidized analogs of prolactin-releasing peptide with a modified C- terminal aromatic ring

V. Prazienkova, A. Ticha, M. Blechova, A. Spolcova, B. Zelezna, L. Maletinska,

. 2016 ; 67 (1) : 121-8.

Jazyk angličtina Země Polsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000318

Prolactin-releasing peptide (PrRP) is an anorexigenic neuropeptide expressed in the brain where it regulates food intake and energy expenditure. The C-terminal Arg-Phe-NH2 of PrRP is crucial for its biological activity. In our previous study, we showed that PrRP analogs myristoylated or palmitoylated at the N- terminus seem to cross the blood-brain barrier and lower food intake following peripheral administration. In this study, myristoylated and palmitoylated PrRP31 analogs with a modified C-terminal Phe were designed and tested. Lipidized analogs containing Phe(31) replaced by aromatic non-coded amino acids or tyrosine revealed high binding affinity to rat pituitary RC-4B/C cells with endogenous PrRP and neuropeptide FF 2 receptors and to CHO-K1 cells overexpressing either PrRP or neuropeptide FF 2 receptors. The analogs also showed strong agonistic properties at the GPR10 receptor using the beta-lactamase reporter gene assay. Moreover, lipidized PrRP analogs, especially those that were palmitoylated, demonstrated strong and long-lasting anorexigenic effects in fasted mice after subcutaneous administration. The most efficient PrRP31 analogs with PheCl2(31), either palmitoylated or myristoylated at the N-terminus, are promising candidates for the study of food disorders, possibly for anti-obesity treatment. Despite the therapeutic potential in targeting central GPR10, the endogenous ligand PrRP cannot cross the blood-brain barrier. Understanding biological activity and transport of novel structural analogs of PrRP with a potential central anorexigenic effect is of key therapeutic significance.

000      
00000naa a2200000 a 4500
001      
bmc17000318
003      
CZ-PrNML
005      
20250521153816.0
007      
ta
008      
170103s2016 pl f 000 0|eng||
009      
AR
035    __
$a (PubMed)27010901
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a pl
100    1_
$a Prazienkova, V $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
245    10
$a Pharmacological characterization of lipidized analogs of prolactin-releasing peptide with a modified C- terminal aromatic ring / $c V. Prazienkova, A. Ticha, M. Blechova, A. Spolcova, B. Zelezna, L. Maletinska,
520    9_
$a Prolactin-releasing peptide (PrRP) is an anorexigenic neuropeptide expressed in the brain where it regulates food intake and energy expenditure. The C-terminal Arg-Phe-NH2 of PrRP is crucial for its biological activity. In our previous study, we showed that PrRP analogs myristoylated or palmitoylated at the N- terminus seem to cross the blood-brain barrier and lower food intake following peripheral administration. In this study, myristoylated and palmitoylated PrRP31 analogs with a modified C-terminal Phe were designed and tested. Lipidized analogs containing Phe(31) replaced by aromatic non-coded amino acids or tyrosine revealed high binding affinity to rat pituitary RC-4B/C cells with endogenous PrRP and neuropeptide FF 2 receptors and to CHO-K1 cells overexpressing either PrRP or neuropeptide FF 2 receptors. The analogs also showed strong agonistic properties at the GPR10 receptor using the beta-lactamase reporter gene assay. Moreover, lipidized PrRP analogs, especially those that were palmitoylated, demonstrated strong and long-lasting anorexigenic effects in fasted mice after subcutaneous administration. The most efficient PrRP31 analogs with PheCl2(31), either palmitoylated or myristoylated at the N-terminus, are promising candidates for the study of food disorders, possibly for anti-obesity treatment. Despite the therapeutic potential in targeting central GPR10, the endogenous ligand PrRP cannot cross the blood-brain barrier. Understanding biological activity and transport of novel structural analogs of PrRP with a potential central anorexigenic effect is of key therapeutic significance.
650    _2
$a zvířata $7 D000818
650    _2
$a hematoencefalická bariéra $x metabolismus $7 D001812
650    _2
$a mozek $x metabolismus $7 D001921
650    _2
$a CHO buňky $7 D016466
650    _2
$a buněčné linie $7 D002460
650    _2
$a Cricetulus $7 D003412
650    _2
$a přijímání potravy $x účinky léků $7 D004435
650    _2
$a lidé $7 D006801
650    _2
$a lipidy $7 D008055
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a neuropeptidy $x metabolismus $x farmakologie $7 D009479
650    _2
$a obezita $x farmakoterapie $x metabolismus $7 D009765
650    _2
$a hormon uvolňující prolaktin $x analogy a deriváty $x metabolismus $x farmakologie $7 D056690
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a receptory neuropeptidů $x metabolismus $7 D018013
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ticha, A $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Blechová, Miroslava $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic. $7 xx0332173
700    1_
$a Spolcova, A $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Zelezna, B $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Maletinska, L $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic. maletin@uochb.cas.cz.
773    0_
$w MED00002908 $t Journal of physiology and pharmacology $x 1899-1505 $g Roč. 67, č. 1 (2016), s. 121-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27010901 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20250521153813 $b ABA008
999    __
$a ok $b bmc $g 1179458 $s 960885
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 67 $c 1 $d 121-8 $i 1899-1505 $m Journal of physiology and pharmacology $n J Physiol Pharmacol $x MED00002908
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...